The use of recombinant activated factor VII in platelet disorders: a critical review of the literature.
作者信息
Franchini Massimo
机构信息
Servizio di Immunoematologia e Medicina Trasfusionale, Dipartimento di Patologia e Medicina di Laboratorio, Azienda Ospedaliero - Universitaria di Parma, Parma, Italy.
出版信息
Blood Transfus. 2009 Jan;7(1):24-8. doi: 10.2450/2008.0015-08.
Abstract
摘要
相似文献
1
The use of recombinant activated factor VII in platelet disorders: a critical review of the literature.重组活化因子VII在血小板疾病中的应用：文献综述
Blood Transfus. 2009 Jan;7(1):24-8. doi: 10.2450/2008.0015-08.
2
The use of recombinant activated factor VII in platelet-associated bleeding.重组活化凝血因子VII在血小板相关出血中的应用。
Hematology. 2008 Feb;13(1):41-5. doi: 10.1179/102453308X315816.
3
Caution with the published database reviews analyzing the off-label use of recombinant activated factor VII (rFVIIa) in cardiac surgery.对已发表的分析重组活化因子 VII（rFVIIa）在心脏手术中未获批准使用情况的数据库综述需谨慎对待。
Transfus Apher Sci. 2010 Oct;43(2):245-6. doi: 10.1016/j.transci.2010.07.014. Epub 2010 Aug 2.
4
Recombinant factor VIIa. An update on its clinical use.重组凝血因子VIIa。其临床应用的最新进展。
Thromb Haemost. 2005 Jun;93(6):1027-35. doi: 10.1160/TH05-01-0032.
5
Use of recombinant factor VII in cardiac surgery.重组因子VII在心脏手术中的应用。
Recent Pat Cardiovasc Drug Discov. 2012 Dec;7(3):216-20. doi: 10.2174/157489012803832874.
6
Modification of biological parameters after treatment with recombinant factor VIIa in a patient with thrombocytopathy due to storage pool disease.重组因子VIIa治疗血小板贮存池病致血小板功能障碍患者后生物学参数的改变
Pediatr Blood Cancer. 2005 Jun 15;44(7):676-8. doi: 10.1002/pbc.20199.
7
[Recombinant factor VIIa in patients with platelet function disorders or thrombocytopenia].血小板功能障碍或血小板减少症患者使用重组凝血因子VIIa
Hamostaseologie. 2007 Sep;27(4):251-62.
8
Recombinant activated factor VII for intractable bleeding post splenectomy in a patient with myeloproliferative disorder.重组活化凝血因子VII用于治疗骨髓增殖性疾病患者脾切除术后的难治性出血。
Blood Coagul Fibrinolysis. 2007 Sep;18(6):577-9. doi: 10.1097/MBC.0b013e3281eec9a1.
9
Use of recombinant factor VIIa in hereditary bleeding disorders.重组凝血因子VIIa在遗传性出血性疾病中的应用。
Curr Opin Hematol. 2001 Sep;8(5):312-8. doi: 10.1097/00062752-200109000-00008.
10
Treatment of bleeding in patients with platelet disorders: is there a place for recombinant factor VIIa?血小板疾病患者出血的治疗：重组凝血因子VIIa有一席之地吗？
Pathophysiol Haemost Thromb. 2002;32 Suppl 1:37-40. doi: 10.1159/000057300.
引用本文的文献
1
Recombinant activated factor VII in a patient with intracranial hemorrhage and severe thrombocytopenia.重组活化因子VII用于一名颅内出血伴严重血小板减少症的患者。
Clin Case Rep. 2021 Oct 10;9(10):e04788. doi: 10.1002/ccr3.4788. eCollection 2021 Oct.
2
Recombinant factor VIIa for hemorrhagic stroke treatment at earliest possible time (FASTEST): Protocol for a phase III, double-blind, randomized, placebo-controlled trial.重组 VII 因子治疗早期出血性脑卒中（FASTEST）：一项 III 期、双盲、随机、安慰剂对照试验方案。
Int J Stroke. 2022 Aug;17(7):806-809. doi: 10.1177/17474930211042700. Epub 2021 Sep 5.
3
Learning the Ropes of Platelet Count Regulation: Inherited Thrombocytopenias.掌握血小板计数调节的诀窍：遗传性血小板减少症
J Clin Med. 2021 Feb 2;10(3):533. doi: 10.3390/jcm10030533.
4
Therapeutic doses of recombinant factor VIIa in hemophilia generates thrombin in platelet-dependent and -independent mechanisms.治疗剂量的重组 VII 因子在血友病中通过血小板依赖和非依赖机制生成凝血酶。
J Thromb Haemost. 2020 Aug;18(8):1911-1921. doi: 10.1111/jth.14881. Epub 2020 Jun 25.
5
Factor VIIa administration in traumatic brain injury: an AAST-MITC propensity score analysis.创伤性脑损伤中凝血因子VIIa的应用：一项美国创伤外科学会-麻省理工学院创伤协作组倾向评分分析
Trauma Surg Acute Care Open. 2018 Mar 22;3(1):e000134. doi: 10.1136/tsaco-2017-000134. eCollection 2018.
6
Bernard-Soulier syndrome: A challenge for anesthetist in an emergency surgery.伯纳德-索利尔综合征：急诊手术中麻醉医生面临的一项挑战。
J Anaesthesiol Clin Pharmacol. 2015 Jul-Sep;31(3):416-7. doi: 10.4103/0970-9185.161709.
7
Recombinant activated factor VII as an additional agent in the management of bleeding in patients with chemotherapy-induced thrombocytopenia.重组活化凝血因子 VII 作为化疗诱导的血小板减少症患者出血管理中的一种附加药物。
Blood Transfus. 2013 Jul;11(3):466-8. doi: 10.2450/2012.0077-12. Epub 2012 Dec 6.
8
Innovative use of recombinant activated factor VII during physical rehabilitation in an Italian child with Glanzmann's thromboasthenia.重组活化凝血因子VII在一名患有Glanzmann血小板无力症的意大利儿童身体康复过程中的创新性应用。
Blood Transfus. 2013 Jan;11(1):143-7. doi: 10.2450/2012.0016-12. Epub 2012 Jul 4.
9
Evidence supporting the use of recombinant activated factor VII in congenital bleeding disorders.支持重组活化凝血因子 VII 用于先天性出血性疾病的证据。
Drug Des Devel Ther. 2010 Jul 21;4:107-16. doi: 10.2147/dddt.s11764.
本文引用的文献
1
Massive pulmonary embolism after treatment with rFVIIa in a thrombocytopenic patient with acute myelogenous leukemia and intractable bleeding.在一名患有急性髓性白血病且有难治性出血的血小板减少患者中，使用重组活化凝血因子VII（rFVIIa）治疗后发生大面积肺栓塞。
Eur J Haematol. 2007 Feb;78(2):173-4. doi: 10.1111/j.1600-0609.2006.00799.x.
2
Use of rFVIIa in 4 children with Glanzmann thrombasthenia.重组活化凝血因子VII（rFVIIa）在4例Glanzmann血小板无力症患儿中的应用。
J Pediatr Hematol Oncol. 2006 Oct;28(10):653-8. doi: 10.1097/01.mph.0000212993.49188.73.
3
Experiences with recombinant activated factor VII in the treatment of severe refractory thrombocytopenia.重组活化因子VII治疗严重难治性血小板减少症的经验。
Pediatr Blood Cancer. 2006 Oct 15;47(5 Suppl):729-30. doi: 10.1002/pbc.21013.
4
Combination therapy with rFVIIa and platelets for hemorrhage in patients with severe thrombocytopenia and alloimmunization.重组活化凝血因子VII（rFVIIa）与血小板联合治疗严重血小板减少症和同种免疫患者的出血。
Am J Hematol. 2006 Mar;81(3):218-9. doi: 10.1002/ajh.20506.
5
Control of bleeding caused by thrombocytopenia associated with hematologic malignancy: an audit of the clinical use of recombinant activated factor VII.血液系统恶性肿瘤相关血小板减少所致出血的控制：重组活化凝血因子VII临床应用审计
Clin Appl Thromb Hemost. 2005 Oct;11(4):401-10. doi: 10.1177/107602960501100406.
6
Recombinant factor VIIa. An update on its clinical use.重组凝血因子VIIa。其临床应用的最新进展。
Thromb Haemost. 2005 Jun;93(6):1027-35. doi: 10.1160/TH05-01-0032.
7
"Off-license" use of recombinant activated factor VII.重组活化凝血因子 VII 的“超适应症”使用
Blood Rev. 2004 Dec;18(4):245-59. doi: 10.1016/j.blre.2003.12.003.
8
The use of rFVIIa in non-haemophilia bleeding conditions in paediatrics. A systematic review.重组活化凝血因子VII（rFVIIa）在儿科非血友病性出血病症中的应用。一项系统评价。
Thromb Haemost. 2004 Oct;92(4):738-46. doi: 10.1160/TH04-03-0163.
9
Recombinant activated factor VII for non-hemophiliac bleeding patients.重组活化凝血因子 VII 用于非血友病出血患者。
Curr Opin Hematol. 2004 May;11(3):198-204. doi: 10.1097/01.moh.0000135405.29702.3c.
10
Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: results of an international survey.对血小板无力症患者进行预防性和治疗性重组凝血因子VIIa给药：一项国际调查结果
J Thromb Haemost. 2004 Jul;2(7):1096-103. doi: 10.1111/j.1538-7836.2004.00767.x.
Zotero 插件